This Phase 2 trial tests an inhaled medication called mosliciguat in 135 people who have both lung scarring (interstitial lung disease) and high blood pressure in the lungs. Participants are randomly assigned to receive either the drug or a placebo for 16 weeks. The study measure…
Phase: PHASE2 • Sponsor: Pulmovant, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC